These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8652130)

  • 1. Geranylgeraniol restores cell proliferation to lovastatin treated C6 glial cells.
    Crick DC; Waechter CJ; Andres DA
    SAAS Bull Biochem Biotechnol; 1996; 9():37-42. PubMed ID: 8652130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells.
    Choi JW; Jung SE
    J Pharmacol Exp Ther; 1999 Apr; 289(1):572-9. PubMed ID: 10087052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells.
    Crick DC; Andres DA; Danesi R; Macchia M; Waechter CJ
    J Neurochem; 1998 Jun; 70(6):2397-405. PubMed ID: 9603204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lovastatin inhibits proliferation of rat mesangial cells.
    O'Donnell MP; Kasiske BL; Kim Y; Atluru D; Keane WF
    J Clin Invest; 1993 Jan; 91(1):83-7. PubMed ID: 8423236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
    Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
    Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation.
    Raiteri M; Arnaboldi L; McGeady P; Gelb MH; Verri D; Tagliabue C; Quarato P; Ferraboschi P; Santaniello E; Paoletti R; Fumagalli R; Corsini A
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1144-53. PubMed ID: 9190847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism.
    Cuthbert JA; Lipsky PE
    Cancer Res; 1997 Aug; 57(16):3498-505. PubMed ID: 9270019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):99-110. PubMed ID: 9221829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lovastatin-induced PC-12 cell differentiation is associated with RhoA/RhoA kinase pathway inactivation.
    Fernández-Hernando C; Suárez Y; Lasunción MA
    Mol Cell Neurosci; 2005 Aug; 29(4):591-602. PubMed ID: 15951198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesol is utilized for protein isoprenylation and the biosynthesis of cholesterol in mammalian cells.
    Crick DC; Andres DA; Waechter CJ
    Biochem Biophys Res Commun; 1995 Jun; 211(2):590-9. PubMed ID: 7794274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome.
    Frenkel J; Rijkers GT; Mandey SH; Buurman SW; Houten SM; Wanders RJ; Waterham HR; Kuis W
    Arthritis Rheum; 2002 Oct; 46(10):2794-803. PubMed ID: 12384940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells.
    Bouterfa HL; Sattelmeyer V; Czub S; Vordermark D; Roosen K; Tonn JC
    Anticancer Res; 2000; 20(4):2761-71. PubMed ID: 10953355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mevalonate pathway: importance in mesangial cell biology and glomerular disease.
    O'Donnell MP; Kasiske BL; Kim Y; Atluru D; Keane WF
    Miner Electrolyte Metab; 1993; 19(3):173-9. PubMed ID: 8232104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geranylgeraniol promotes entry of UT-2 cells into the cell cycle in the absence of mevalonate.
    Crick DC; Andres DA; Waechter CJ
    Exp Cell Res; 1997 Mar; 231(2):302-7. PubMed ID: 9087171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
    Fisher JE; Rogers MJ; Halasy JM; Luckman SP; Hughes DE; Masarachia PJ; Wesolowski G; Russell RG; Rodan GA; Reszka AA
    Proc Natl Acad Sci U S A; 1999 Jan; 96(1):133-8. PubMed ID: 9874784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells.
    Ownby SE; Hohl RJ
    Lipids; 2002 Feb; 37(2):185-92. PubMed ID: 11908910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
    Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
    Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of geranylgeraniol for protein isoprenylation in C6 glial cells.
    Crick DC; Waechter CJ; Andres DA
    Biochem Biophys Res Commun; 1994 Nov; 205(1):955-61. PubMed ID: 7999138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
    Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
    Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.